Results 171 to 180 of about 29,367 (217)
Time-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis. [PDF]
J Bone Miner MetabMori S +4 more
europepmc +1 more source
Risk factors for denosumab-related osteonecrosis of the jaw: a pharmacovigilance study using the U.S. FDA adverse event reporting system database. [PDF]
Front Endocrinol (Lausanne)Bai H +5 more
europepmc +1 more source
Bone Mineral Density Measurements and Fracture Prediction in the Very Elderly. [PDF]
CureusBorenstein J +3 more
europepmc +1 more source
Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease. [PDF]
Front Endocrinol (Lausanne)Li H +9 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Treatments in Endocrinology, 2005
Alendronate/colecalciferol 70 mg/2800 IU, a once-weekly tablet containing the bisphosphonate alendronate and colecalciferol (the precursor of the biologically active form of vitamin D), has been approved for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis.
Neil A, Reynolds, Monique P, Curran
openaire +2 more sources
Alendronate/colecalciferol 70 mg/2800 IU, a once-weekly tablet containing the bisphosphonate alendronate and colecalciferol (the precursor of the biologically active form of vitamin D), has been approved for the treatment of osteoporosis in women and for increasing bone mass in men with osteoporosis.
Neil A, Reynolds, Monique P, Curran
openaire +2 more sources
Bone, 2020
Alendronate was synthesized in 1970s in a search for inhibitors of calcification. Istituto Gentili investigators identified it as a potent inhibitor of bone resorption and obtained a patent covering its use in the treatment of osteoporosis and other disorders of excessive bone resorption in the 1980s.
Steven R. Cummings +3 more
openaire +2 more sources
Alendronate was synthesized in 1970s in a search for inhibitors of calcification. Istituto Gentili investigators identified it as a potent inhibitor of bone resorption and obtained a patent covering its use in the treatment of osteoporosis and other disorders of excessive bone resorption in the 1980s.
Steven R. Cummings +3 more
openaire +2 more sources
2013
This chapter is a review on physical and chemical properties, methods of preparation, analysis, as well as pharmacodynamics and pharmacokinetics of Alendronate sodium (4-amino-1-hydroxybutane-1,1-diphosphonic acid sodium salt), a bone metabolism regulator, indicated for the treatment of excessive bone resorption and osteoporosis.
Gennady, Ananchenko +2 more
openaire +2 more sources
This chapter is a review on physical and chemical properties, methods of preparation, analysis, as well as pharmacodynamics and pharmacokinetics of Alendronate sodium (4-amino-1-hydroxybutane-1,1-diphosphonic acid sodium salt), a bone metabolism regulator, indicated for the treatment of excessive bone resorption and osteoporosis.
Gennady, Ananchenko +2 more
openaire +2 more sources
JCR: Journal of Clinical Rheumatology, 1997
Alendronate is an aminobisphosphonate that was approved recently for the treatment of osteoporosis. Studies in ovariectomized rats and baboons have demonstrated the efficacy of this drug in animal models of osteoporosis. Alendronate prevented bone loss and increased bone mass and bone strength, relative to estrogen-deficient controls. Histomorphometric
openaire +3 more sources
Alendronate is an aminobisphosphonate that was approved recently for the treatment of osteoporosis. Studies in ovariectomized rats and baboons have demonstrated the efficacy of this drug in animal models of osteoporosis. Alendronate prevented bone loss and increased bone mass and bone strength, relative to estrogen-deficient controls. Histomorphometric
openaire +3 more sources
Pharmacokinetics of Alendronate
Clinical Pharmacokinetics, 1999Alendronate (alendronic acid; 4-amino-1-hydroxybutylidene bisphosphonate) has demonstrated effectiveness orally in the treatment and prevention of postmenopausal osteoporosis, corticosteroid-induced osteoporosis and Paget's disease of the bone. Its primary mechanism of action involves the inhibition of osteoclastic bone resorption. The pharmacokinetics
A G, Porras, S D, Holland, B J, Gertz
openaire +2 more sources
Drugs of Today, 2003
Alendronate, a bisphosphonate that potently inhibits bone resorption, has been shown in long-term clinical trials to be an effective treatment for osteoporosis, increasing bone mineral density and substantially reducing the incidence of both vertebral and nonvertebral fractures, including hip fractures, mostly using a daily dosage regimen.
openaire +2 more sources
Alendronate, a bisphosphonate that potently inhibits bone resorption, has been shown in long-term clinical trials to be an effective treatment for osteoporosis, increasing bone mineral density and substantially reducing the incidence of both vertebral and nonvertebral fractures, including hip fractures, mostly using a daily dosage regimen.
openaire +2 more sources